Allurion to Combine GLP-1 Therapy with Balloon for Obesity Treatment
Allurion to Combine GLP-1 Therapy with Balloon for Obesity Treatment Allurion Technologies, Inc. (NYSE: ALUR), a company focused on combating obesity, has announced plans to launch a clinical study exploring the combination of the Allurion Balloon with GLP-1 agonists. The…
Oneview Healthcare Launches ‘Ovie’ Care Assistant to Ease Nursing Burden
Oneview Healthcare Launches ‘Ovie’ Care Assistant to Ease Nursing Burden Oneview Healthcare has launched Ovie, a groundbreaking GenAI product designed to offer personalized, real-time support for patients and their families during hospital stays. Oneview Healthcare has launched Ovie, a transformative…
WELIREG® (belzutifan) Gains First European Commission Approval for Two Indications
WELIREG® (belzutifan) Gains First European Commission Approval for Two Indications Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that the European Commission (EC) has conditionally approved WELIREG® (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α)…
XRHealth Acquires RealizedCare, Expanding to Largest AI-Driven Therapeutic XR Platform
XRHealth Acquires RealizedCare, Expanding to Largest AI-Driven Therapeutic XR Platform XRHealth, a leader in therapeutic virtual reality (VR), mixed reality (MR), and extended reality (XR) solutions, has acquired the immersive digital therapeutics company RealizedCare. This acquisition enhances XRHealth’s AI-powered, value-based…
GeneDx Reports Q4 and 2024 Financial Results, Provides 2025 Guidance
GeneDx Reports Q4 and 2024 Financial Results, Provides 2025 Guidance GeneDx Holdings Corp. (Nasdaq: WGS), a leader in genomic testing for improved health outcomes, reported its financial results for the fourth quarter and full year of 2024. The company highlighted…
Galderma’s Nemluvio® (Nemolizumab) Approved for Atopic Dermatitis and Prurigo Nodularis in the UK and Switzerland
Galderma’s Nemluvio® (Nemolizumab) Approved for Atopic Dermatitis and Prurigo Nodularis in the UK and Switzerland Galderma has announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Swissmedic have granted marketing authorization for Nemolizumab, a monoclonal antibody…
CancerX Unveils 2025 Accelerator to Propel Oncology Innovation
CancerX Unveils 2025 Accelerator to Propel Oncology Innovation CancerX, a public-private partnership aimed at accelerating cancer innovation, has announced the launch of its 2025 Accelerator cohort. This year’s group includes a remarkable selection of digital health and artificial intelligence startups…
ICC Tribunal Rules in Favor of AOP Health in BESREMi® Arbitration Case
ICC Tribunal Rules in Favor of AOP Health in BESREMi® Arbitration Case An International Chamber of Commerce (ICC) tribunal has issued a partial final award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in an ongoing legal dispute with…
Pneuma Respiratory Enhances Inhaled Therapies for Better Respiratory Health
Pneuma Respiratory Enhances Inhaled Therapies for Better Respiratory Health Pneuma Respiratory, a leading med-tech and pharmaceutical company, is pioneering innovative solutions in inhaled respiratory therapeutics aimed at transforming respiratory care. With a focus on treating smoking-related lung conditions, Pneuma is…
Cellistic Unveils Allo Chassis™: Immune-Cloaked iPSC Cell Lines for Cost-Effective Cell Therapy
Cellistic Unveils Allo Chassis™: Immune-Cloaked iPSC Cell Lines for Cost-Effective Cell Therapy Cellistic, a leader in iPSC-based off-the-shelf cell therapy development and manufacturing services, has introduced its innovative Allo Chassis™—a new line of immune-cloaked iPSC cell lines derived from CD34+…
InnoCare Announces Phase III Study Approval of ICP-248 and Orelabrutinib for CLL/SLL in China
InnoCare Announces Phase III Study Approval of ICP-248 and Orelabrutinib for CLL/SLL in China InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focused on developing therapies for cancer and autoimmune diseases, has announced that the Center for Drug…
BioIntelliSense Teams Up with Hicuity Health for Scalable Continuous Patient Monitoring
BioIntelliSense Teams Up with Hicuity Health for Scalable Continuous Patient Monitoring BioIntelliSense, a leader in continuous health monitoring and clinical intelligence, has announced a strategic partnership with Hicuity Health, a leading provider of tech-enabled virtual care services. This collaboration aims…